Following the publication of the Research Article by Sanjeev Kaul, Kirk J Wojno, Steven Stone, Brent Evans, Ryan Bernhisel, Stephanie Meek, Richard E D'Anna, Jeffrey Ferguson, Jeffrey Glaser, Todd M Morgan, Jeremy Lieb, Robert Yan, Todd Cohen & Behfar Ehdaie, titled ‘Clinical outcomes in men with prostate cancer who selected active surveillance usinga clinical cell cycle risk score’ in the 2019 issue of Personalized Medicine (Per. Med. 16(6), 491–499 [2019]), it has been brought to our attention that the first sentence of the financial & competing interests disclosure was incorrect.
This was originally displayed as:
“This work was financially supported by Myriad Genetics, Inc. B Evans, R Bernhisel, S Stone, T Cohen and S Meek were all employed by Myriad Genetics at the time of this study.”
This has now been corrected to:
“This work was financially supported by the NIH (grant number: P30 CA008748) and Myriad Genetics, Inc. B Evans, R Bernhisel, S Stone, T Cohen and S Meek were all employed by Myriad Genetics at the time of this study.”
The authors would like to sincerely apologize for any confusion or inconvenience this may have caused our readers.